- Emtricitabine/rilpivirine/tenofovir
-
Emtricitabine/rilpivirine/tenofovir Combination of Emtricitabine Nucleoside analog reverse transcriptase inhibitor Rilpivirine Non-nucleoside reverse transcriptase inhibitor Tenofovir disoproxil fumarate Nucleoside analog reverse transcriptase inhibitor Clinical data Pregnancy cat. ? Legal status ℞-only (US) Routes Oral Identifiers ATC code ? (what is this?) (verify) Emtricitabine/rilpivirine/tenofovir (trade name Complera, Eviplera) is a fixed dose combination of antiretroviral drugs for the treatment of HIV.[1] The drug was co-developed by Gilead Sciences and Johnson & Johnson's Tibotec division and was approved by the Food and Drug Administration in August 2011 for patients who have not previously been treated for HIV.[2] It is available as a once-a-day single tablet.
References
- ^ "Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination". Food and Drug Administration. August 10, 2011. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm267592.htm.
- ^ "FDA approves Gilead-J&J HIV pill Complera". Business Week. August 10, 2011. http://www.businessweek.com/ap/financialnews/D9P1ERH80.htm.
This antiinfective drug article is a stub. You can help Wikipedia by expanding it.